Board of Directors
Mark A. Goldsmith, M.D., Ph.D., Chairman
Founding President, CEO and Director, Revolution Medicines
Previously, Partner with Third Rock Ventures in its West Coast office. Prior to this, Dr. Goldsmith served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies.
James E. Audia, Ph.D.
Executive Director of the Chicago Biomedical Consortium
Dr. Jim Audia currently serves as Executive Director of the Chicago Biomedical Consortium, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation in the greater Chicago area. He joined the CBC after a nearly seven-year tenure as Constellation Pharmaceuticals’ chief scientific officer, where he oversaw the successful evolution of the company’s R&D efforts from a strong scientific base to a robust portfolio of clinical-stage assets and pre-clinical programs. Dr. Audia had joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. He held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 17 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 100 issued U.S. patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly. Dr. Audia currently serves as a scientific advisor for Sage Therapeutics, Ribon Therapeutics, and the Tau Consortium of the Rainwater Foundation.
Anthony Evnin, Ph.D.
Dr. Evnin is a Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He currently serves on the boards of AVEO Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc., and Pharmos Corporation as well as a number of private companies. Dr. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, and a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Dr. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.
Managing Partner and Founder, The Column Group
Peter has 30 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helped found companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Immune Design, and Gritstone and has served on the Boards of several other biotechnology companies, including Seragon Pharmaceuticals (Chairman), Aragon Pharmaceuticals (Chairman), Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.
Robert Tepper, M.D.
Partner, Third Rock Ventures
Dr. Tepper co-founded Third Rock Ventures in 2007 and serves as a Partner. Dr. Tepper works actively with portfolio companies to shape their scientific strategy. In this capacity Dr. Tepper worked as CSO of Constellation from April 2008 to October 2009. Prior to joining Third Rock Ventures, Dr. Tepper was President of R&D at Millennium Pharmaceuticals and co-founder of Cell Genesys/Abgenix. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, Tufts Medical School, and a member of the Research Advisory Council of Massachusetts General Hospital.
Constellation’s founders and scientific advisors are pioneers, authorities and thought leaders within the fields of epigenetics, drug discovery, and clinical medicine. They have made innumerable contributions to our understanding of epigenetic biology and to the development of novel therapeutics.
Danny Reinberg, Ph.D.
Terry and Mel Karmazin Professor, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine
Howard Hughes Medical Institute Investigator
Member of the National Academy of Sciences
David Allis, Ph.D.
Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University
Member of the National Academy of Sciences
Yang Shi, Ph.D.
Professor of Cell Biology, HMS and Merton Bernfield Professor of Neonatology at Children’s Hospital
Scientific Advisory Board
David Livingston, M.D.
Deputy Director, Dana Farber Harvard Cancer Center
Professor of Medicine and Genetics, Harvard Medical School
Scott Lowe, Ph.D.
Chair of the Geoffrey Beene Cancer Research Center
Cancer Biology and Genetics Program, Sloan-Kettering Institute
Howard Hughes Medical Institute
Robert Schreiber, Ph.D.
Alumni Endowed Professor of Pathology and Immunology
Professor of Molecular Microbiology
Director of the Center for Human Immunology and Immunotherapy programs, Washington University School of Medicine
Padmanee Sharma, M.D., Ph.D.
Professor, Department of Genitourinary Medical Oncology, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX